Department of Internal Medicine, Department of Nephrology, Faculty of Medicine, Afyonkarahisar Health Science University, Afyonkarahisar, Turkey.
Eur Rev Med Pharmacol Sci. 2023 Jan;27(2):642-648. doi: 10.26355/eurrev_202301_31065.
We aimed to investigate the prognostic values of systemic immune inflammation index and pan-immune inflammation value in patients with idiopathic low and moderate risk membranous nephropathy.
All membranous nephropathy patients diagnosed in the nephrology clinic between January 2015 and January 2022 were reviewed retrospectively. Patients with idiopathic membranous nephropathy were included. The patients were divided into two groups; the complete remission group: whose proteinuria decreased below 0.3 g/day and serum albumin level above 3.5 g/dL after 6 months of conservative treatment, and the non-remission group: all other patients. Groups were compared in terms of systemic immune inflammation index and pan-immune inflammation value.
Patients in the non-remission group had significantly higher systemic immune-inflammation index (SII) and pan-immune-inflammation value (PIV) than patients in the complete remission group (p<0.05). An SII of 1,056.2 was found to have 63.6% sensitivity and 100% specificity in predicting non-remission, and a PIV of 447.4 was found to have 100% sensitivity and 70.6% specificity in predicting non-remission.
SII and PIV are reliable markers for predicting non-remission in patients with low and moderate risk idiopathic MN.
本研究旨在探讨全身性免疫炎症指数和全免疫炎症值在特发性低危和中危膜性肾病患者中的预后价值。
回顾性分析 2015 年 1 月至 2022 年 1 月在我院肾内科诊断的所有膜性肾病患者。纳入特发性膜性肾病患者。患者分为两组:完全缓解组:经 6 个月保守治疗后蛋白尿降至 0.3 g/天以下,血清白蛋白水平>3.5 g/dL;未缓解组:其他所有患者。比较两组患者的全身性免疫炎症指数和全免疫炎症值。
未缓解组患者的全身性免疫炎症指数(SII)和全免疫炎症值(PIV)显著高于完全缓解组(p<0.05)。SII 为 1056.2 时,预测未缓解的敏感性为 63.6%,特异性为 100%;PIV 为 447.4 时,预测未缓解的敏感性为 100%,特异性为 70.6%。
SII 和 PIV 是预测特发性低危和中危 MN 患者缓解不良的可靠标志物。